Quality-of-life outcomes in high-risk prostate cancer patients treated with helical tomotherapy in a hypofractionated radiation schedule with long-term androgen suppression

Current Oncology

Volumn 19, Issue 3, 2012, Pages

  Pervez, Nadeem ^a   Krauze, A V ^a   Yee, D ^a   Parliament, M ^a   Mihai, A ^a   Ghosh, S ^a   Joseph, K ^a   Murtha, A ^a   Amanie, J ^a   Kamal, M ^b   Pearcey, R ^a  

^a CROSS CANCER INSTITUTE   (Canada)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

AST; Hypofractionation; Imrt; Prostate cancer; Quality of life; Toxicity

Indexed keywords

ADULT; ADVERSE OUTCOME; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER RADIOTHERAPY; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; SEXUAL FUNCTION; TOMOTHERAPY; TREATMENT OUTCOME;

EID: 84930477762     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.915     Document Type: Article

References (40)

1. Canadian Cancer Society's Steering Committee. Canadian Cancer Statistics 2010. Toronto, ON: Canadian Cancer Society; 2010.
2. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358:1250-61.
3. Penson DF. Quality of life after therapy for localized prostate cancer. Cancer J 2007;13:318-26.
4. Schulman C. Assessing the attitudes to prostate cancer treatment among European male patients. BJU Int 2007;100(suppl 1):6-11.
5. Diefenbach MA, Mohamed NE. Regret of treatment decision and its association with disease-specific quality of life following prostate cancer treatment. Cancer Invest 2007;25:449-57.
6. Frank SJ, Pisters LL, Davis J, Lee AK, Bassett R, Kuban DA. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. J Urol 2007;177:2151-6.
7. Litwin MS, Gore JL, Kwan L, et al. Quality of life after surgery, external beam irradiation, or brachytherapy for earlystage prostate cancer. Cancer 2007;109:2239-47.
8. Huang GJ, Sadetsky N, Penson DF. Health related quality of life for men treated for localized prostate cancer with longterm followup. J Urol 2010;183:2206-12.
9. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an eortc study): a phase iii randomised trial. Lancet 2002;360:103-6.
10. Hanks GE, Pajak TF, Porter A, et al. Phase iii trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21:3972-8.
11. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999;43:1095-101.
12. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the MD Anderson phase iii randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-105.
13. Storey MR, Pollack A, Zagars G, Smith L, Antolak J, Rosen I. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000;48:635-42.
14. Eade TN, Hanlon AL, Horwitz EM, Buyyounouski MK, Hanks GE, Pollack A. What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys 2007;68:682-9.
15. Symon Z, Griffith KA, McLaughlin PW, Sullivan M, Sandler HM. Dose escalation for localized prostate cancer: substantial benefit observed with 3D conformal therapy. Int J Radiat Oncol Biol Phys 2003;57:384-90.
16. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001;50:1021-31.
17. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 2002;52:6-13.
18. Bentzen SM, Ritter MA. The alpha/beta ratio for prostate cancer: what is it, really? Radiother Oncol 2005;76:1-3.
19. Williams SG, Taylor JM, Liu N, et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 2007;68:24-33.
20. Amer AM, Mott J, Mackay RI, et al. Prediction of the benefits from dose-escalated hypofractionated intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2003;56:199-207.
21. Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys 2005;63:1463-8.
22. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007;68:1424-30.
23. Yeoh EE, Holloway RH, Fraser RJ, et al. Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase iii randomized trial. Int J Radiat Oncol Biol Phys 2006;66:1072-83.
24. Lips I, Dehnad H, Kruger AB, et al. Health-related quality of life in patients with locally advanced prostate cancer after 76 Gy intensity-modulated radiotherapy vs. 70 Gy conformal radiotherapy in a prospective and longitudinal study. Int J Radiat Oncol Biol Phys 2007;69:656-61.
25. Junius S, Haustermans K, Bussels B, et al. Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase i/ii feasibility study. Radiat Oncol 2007;2:29.
26. Kupelian PA, Reddy CA, Klein EA, Willoughby TR. Shortcourse intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 2001;51:988-93.
27. Namiki S, Ishidoya S, Tochigi T, et al. Health-related quality of life after intensity modulated radiation therapy for localized prostate cancer: comparison with conventional and conformal radiotherapy. Jpn J Clin Oncol 2006;36:224-30.
28. Beckendorf V, Guerif S, Le Prisé E, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of getug 06 randomized trial. Int J Radiat Oncol Biol Phys 2011;80:1056-63.
29. Al-Mamgani A, van Putten WL, van der Wielen GJ, Levendag PC, Incrocci L. Dose escalation and quality of life in patients with localized prostate cancer treated with radiotherapy: long-term results of the Dutch randomized dose-escalation trial (ckto 96-10 trial). Int J Radiat Oncol Biol Phys 2011;79:1004-12.
30. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Brook RH. The ucla Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care 1998;36:1002-12.
31. Pervez N, Small C, MacKenzie M, et al. Acute toxicity in highrisk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2010;76:57-64.
32. Lawton CAF. Pelvic Nodal Consensus CTV Contours: High Risk/Locally Advanced Adenocarcinoma of the Prostate. Philadelphia, PA: Radiation Therapy Oncology Group; 2008. [Available for download at: http://www.rtog.org/CoreLab/ContouringAtlases/ProstatePelvicLymphNodes.aspx; cited: April 25, 2012]
33. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988;44:1049-60.
34. Hanlon AL, Watkins Bruner D, Peter R, Hanks GE. Quality of life study in prostate cancer patients treated with threedimensional conformal radiation therapy: comparing late bowel and bladder quality of life symptoms to that of the normal population. Int J Radiat Oncol Biol Phys 2001;49:51-9.
35. Katz G, Rodriguez R. Changes in continence and health-related quality of life after curative treatment and watchful waiting of prostate cancer. Urology 2007;69:1157-60.
36. Smith LJ, Mulhall JP, Deveci S, Monaghan N, Reid MC. Sex after seventy: a pilot study of sexual function in older persons. J Sex Med 2007;4:1247-53.
37. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, Waite LJ. A study of sexuality and health among older adults in the United States. N Engl J Med 2007;357:762-74.
38. Zelefsky MJ, Cowen D, Fuks Z, et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999;85:2460-8.
39. Brown MW, Brooks JP, Albert PS, Poggi MM. An analysis of erectile function after intensity modulated radiation therapy for localized prostate carcinoma. Prostate Cancer Prostatic Dis 2007;10:189-93.
40. van der Wielen GJ, van Putten WL, Incrocci L. Sexual function after three-dimensional conformal radiotherapy for prostate cancer: results from a dose-escalation trial. Int J Radiat Oncol Biol Phys 2007;68:479-84.